Polyactiva

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Also australiatimes.com

Morse Micro raises $88 million for long-range Wi-Fi chips

Sydney chipmaker Morse Micro has banked an $88 million Series C led by Japan's MegaChips, with the national reconstruction fund and several existing backers also participating; funds will drive growth and future chip development.

Also Startup Daily·builtinsydney.au·semiiphub.com·Forbes Australia·morsemicro.com·Forbes Australia·SmartCompany·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Forbes Australia·smallbizai.au

Brandon Capital closes $439m fund with $150m leg up from the NRFC

Australia's NRFC has injected $150m into Brandon Capital's sixth life-science vehicle, lifting it to a $439m close; past NRFC cheques to local deep-tech firms are also recapped.

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m

Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.

2025 state of raising: $1.8 billion in – as late-stage deals boom

Tracxn figures show Australian tech funding reached $1.8 billion by mid-2025, powered by large late-stage rounds at Protecht, Airwallex, Harrison AI and Advancell, while seed and early-stage raising fell away sharply.

PolyActiva Secures $40M in Series C Financing to Advance Innovation in Sustained Ocular Drug Delivery

Australian biotech PolyActiva has raised A$40 million in Series C funding to advance its PA5108 ocular implant and PREZIA platform, backed by the National Reconstruction Fund Corporation and Brandon Capital.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·polyactiva.com·Startup Daily·ophthalmologybreakingnews.com·Forbes Australia

NRF backs PolyActiva in $40 million raise for dissolvable eye implants

Biotech PolyActiva has banked a Series C round led by the National Reconstruction Fund with Brandon Capital, funding late-stage trials of its dissolvable glaucoma implant and a consolidated Melbourne site.

Also Startup Daily

National Reconstruction Fund Corporation invests $27 million in glaucoma treatment device maker

Citing AFR reporting, the publisher relays that the federal reconstruction investor is set to announce a stake in a glaucoma treatment developer, alongside venture co-funding, and plugs its June funding panel.

PolyActiva Showcases Promising Clinical Data Highlighting its Polymer Technology's Potential to Transform Glaucoma Care

PolyActiva reported Phase 2 results showing its PA5108 ocular implant lowered eye pressure safely in glaucoma patients, with a phase 2b trial planned, after presentations at two ophthalmology conferences.

Manufacturing news briefs – stories you might have missed

Roundup of Australian manufacturing news: OncoSil, K-TIG and Aurora Labs complete or commit raises, Amplia opens an offer, Siemens agrees to buy Altair, CSIRO unveils a printed-solar facility, and a WA medical alliance grows.

Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential

CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.

Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period

PolyActiva's glaucoma implant was well tolerated in a Phase I trial and a Phase II study is underway; the Melbourne biotech is backed by Brandon Capital's MRCF and Yuuwa Capital.

PolyActiva completes recruitment in key Phase I glaucoma implant safety study.

PolyActiva finished enrolling patients in its Phase I glaucoma implant trial and closed a AU$10 million raise from existing backers including the MRCF and Yuuwa Capital to fund further clinical studies.

Also Brandon BioCatalyst portfolio

Brandon Capital scores $210m for fifth medical research fund

Brandon Capital's blog reports a first close of $210 million toward its $250 million MRCF 5 biotech fund, with super funds and CSL backing, and recalls past portfolio sales of Spinifex and Fibrotech.

Also Brandon BioCatalyst portfolio

Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional

Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily